GUTS Company Profile and Key Details

Fractyl Health, Inc. Common Stock (NASDAQ:GUTS) closed at $1.85 USD, losing -$0.06 (-3.14%) from the previous close of $1.91. The stock is currently mid-range between its 52-week high and low $0.82 and $3.03. With a market capitalization of about $133.56 million, Fractyl Health, Inc. Common Stock is classified as a micro-cap and shows higher-than-market volatility (beta ~1.62). Key stats such as the average daily volume over the past year has been around 2.96 million shares, in line with its 52-week average. Headquartered in Lexington, MA, Fractyl Health, Inc. Common Stock operates in the Healthcare sector and the Biotechnology industry. Led by CEO Harith Rajagopalan, the company employs approximately 107 people and listed since February 02, 2024. Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity.

Short-term trend indicators are bearishly aligned (SMA20 -9.86%, SMA50 3.09%, SMA200 23.93%). The stock’s 14-day RSI is 41.95 (neutral), while the ATR of 0.15 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -36.96% below its high and over 131.52% above its low. Average 10-day trading volume of 2.57 million shares is in line with the 3-month average of 2.80 million, indicating normal recent market interest.

Fractyl Health, Inc. Common Stock generated EPS of -$2.27 over the past year. Five-year average earnings growth is -12.32%. Wall Street analysts project EPS growth of 26.27% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 6 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $10.00 to $3.60. The high target offers 423.56% upside. The low target suggests 88.48% downside. The mean target is $7.51. This offers 293.19% upside. Fractyl Health, Inc. Common Stock earnings surprise history is a mixed track record. The quarter that ended November 12, 2025, missed forecasts by 2.94%. The prior quarter beat by 43.24%. Over the last six quarters, Apple has recorded several small beats. These include -21.74% in August 14, 2024.

Fractyl Health, Inc. Common Stock last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.11. This means the shares are trading above this model’s fair value.

Fractyl Health, Inc. Common Stock has 70.88 million shares outstanding. The public float is 27.94 million shares, elevated short interest at 8.20% of float. This equals 2.00 million shares. The short ratio is 8.02 days. Institutional investors hold 55.71% of the float. Insiders own 3.34%. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Fractyl Health, Inc. Common Stock trades at a P/E ratio of -0.98, slightly below the S&P 500 average, with a price-to-sales ratio of 44403.98 and a price-to-book ratio of -37.54 indicating negative book value, which may reflect financial stress. The P/FCF stands at -1.53, also above market averages.

Fractyl Health, Inc. Common Stock (NASDAQ:GUTS) shares are down -13.18% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Fractyl Health, Inc. Common Stock trading at a premium to the broader market with a P/E of -0.98. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $7.51, suggesting 293.19% upside. Our AI forecast model points to short-term weakness (-10.47% over two weeks), a medium-term fall (-60.21% over three months), and a longer-term gain (171.73% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Fractyl Health, Inc. Common Stock stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -10.47%, with price expected at $1.71 by February 03, 2026, within a range of $1.58 to $1.85 3-Month Outlook: Projected fall of -60.21%, reaching $0.76 by April 16, 2026, with a range of $0.62 to $0.87. 1-Year Outlook: Projected gain of 171.73%, with price at $5.19 by January 15, 2027, within a range of $1.26 to $5.38.